Radioembolization plus Immune Checkpoint Inhibitor Therapy Compared with Radioembolization plus Tyrosine Kinase Inhibitor Therapy for the Treatment of Hepatocellular Carcinoma.

Purpose: To investigate if combination therapy with immune checkpoint inhibitor (ICI) and yttrium-90 (Y) radioembolization results in superior outcomes than those yielded by tyrosine kinase inhibitor (TKI) therapy and Y for the treatment of intermediate- to advanced-stage hepatocellular carcinoma (HCC).

Methods: A retrospective review of patients presented at an institutional multidisciplinary liver tumor board between January 1, 2012 and August 1, 2023 was conducted. In total, 44 patients with HCC who underwent Y 4 weeks within initiation of ICI or TKI therapy were included.

Individual Socioeconomic Factors Have a Greater Impact on End-of-Life Care Outcomes Than Regional Factors.

End-of-life (EoL) care provided to Americans in urban and rural settings is distinct in terms of both available and delivered services. However, much less is known about which geographic, demographic, and health indicators are associated with disparities in EoL care and how individual versus regional characteristics influence quality of care (QoC). This study aimed to assess how regionality, rurality, and individual socioeconomic factors are associated with QoC in the last month of life (LML).